Last reviewed 2026-04-22 · How we verify

tenofovir + emtricitabine + atazanavir-ritonavir

tenofovir + emtricitabine + atazanavir-ritonavir is a Antiretroviral combination (NRTI + PI/r) Small molecule drug developed by Juan A. Arnaiz. It is currently FDA-approved for HIV-1 infection in treatment-naïve and treatment-experienced adults, HIV-1 infection in combination antiretroviral therapy.

This combination inhibits HIV reverse transcriptase and protease to block viral replication at multiple steps.

This combination inhibits HIV reverse transcriptase and protease to block viral replication at multiple steps. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults, HIV-1 infection in combination antiretroviral therapy.

At a glance

Mechanism of action

Tenofovir and emtricitabine are nucleoside reverse transcriptase inhibitors (NRTIs) that prevent HIV from converting its RNA genome into DNA. Atazanavir is a protease inhibitor that blocks the HIV protease enzyme needed to process viral proteins, while ritonavir acts as a pharmacokinetic booster to increase atazanavir levels. Together, these agents suppress HIV replication through complementary mechanisms.

Approved indications

• HIV-1 infection in treatment-naïve and treatment-experienced adults
• HIV-1 infection in combination antiretroviral therapy

Common side effects

• Nausea
• Diarrhea
• Headache
• Hyperbilirubinemia
• Rash
• Renal impairment (tenofovir-related)
• Bone density loss

Key clinical trials

• Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
• A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
• Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
• Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
• Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV (PHASE4)
• Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia (NA)
• Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses (PHASE2)
• A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• tenofovir + emtricitabine + atazanavir-ritonavir CI brief — competitive landscape report
• tenofovir + emtricitabine + atazanavir-ritonavir updates RSS · CI watch RSS
• Juan A. Arnaiz portfolio CI

Frequently asked questions about tenofovir + emtricitabine + atazanavir-ritonavir

Related

• Drug class: All Antiretroviral combination (NRTI + PI/r) drugs
• Target: All drugs targeting HIV reverse transcriptase, HIV protease
• Manufacturer: Juan A. Arnaiz — full pipeline
• Therapeutic area: All drugs in Infectious Disease / Virology
• Indication: Drugs for HIV-1 infection in treatment-naïve and treatment-experienced adults
• Indication: Drugs for HIV-1 infection in combination antiretroviral therapy
• Compare: tenofovir + emtricitabine + atazanavir-ritonavir vs similar drugs
• Pricing: tenofovir + emtricitabine + atazanavir-ritonavir cost, discount & access